Natera, Inc. (NTRA) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $207.19. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of NTRA = $1,247.58 (+502.1% from the current price, the stock appears undervalued). Analyst consensus target is NTRA = $250 (+20.5% upside).
Valuation: NTRA trades at a trailing Price-to-Earnings (P/E) of -135.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.04.
Financials: revenue is $2.3B, +41.5%/yr average growth. Net income is $208M (loss), growing at +22.5%/yr. Net profit margin is -9% (negative). Gross margin is 64.8% (+20.4 pp trend).
Balance sheet: total debt is $214M against $1.7B equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 3.39 (strong liquidity). Debt-to-assets is 8.5%. Total assets: $2.5B.
Analyst outlook: 25 / 27 analysts rate NTRA as buy (93%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 52/100 (Partial), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 80/100 (Pass), Future 94/100 (Pass), Income 10/100 (Fail).
